NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Onco’Zine – ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of AML
Peter Hofland, Ph.D. Dec 8, 2020 https://www.oncozine.com/ash-2020-preclinical-models-identifies-cd74-as-potential-target-for-the-treatment-of-aml/ Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1...
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
South San Francisco, Calif., Dec. 8, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
South San Francisco, Calif., Dec. 7, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents at the American Society of Hematology (ASH) 2020 – Poster Presentation
Download the Presentation, Click Here
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular...
Bill Newell, CEO Interviewed by Moira Gunn on TechNation Radio Podcast – Episode 20-40 The Pivot From Hep B to COVID-19
TechNation’s Moria Gunn speaks with CEO Bill Newell about Sutro’s novel approach to treating cancer. Listen on Apple Podcasts
KOL Discussion of STRO-002 Data – PowerPoint Presentation & Audio Replay
To download the presentation, Click Here Audio Replay is assessable for 30 days to registrants, Click Here
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
- Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose levels–including 1 CR, 3 cPRs and 6 uPRs - - Disease control rate at 12 weeks is 74% (23/31) and 10 patients remained on treatment - - Dose-expansion has been intiated to...
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro’s Board - SOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and...
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
– Discussion of STRO-002 Data and Program Expansion at 5pm ET / 2pm PTon Dec. 3rd – SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
